B cells are necessary to maintain disease activity in relapsing multiple sclerosis (MS) and produce matrix metallopeptidase-9 (MMP-9), which disrupts the blood-brain barrier. MMP-9 protein expression was increased and expression of microRNA-320a (miR-320a), which targets MMP-9 mRNA, was significantly decreased in B lymphocytes of MS patients during a disease relapse compared to remission. Functional significance of these findings was demonstrated by transfecting human B lymphocytes with miR320a inhibitor, which led to increased MMP-9 expression and secretion. In summary, expression of miR-320a is decreased in B cells of MS patients and may contribute to increased blood-brain barrier permeability and neurological disability.
Introduction
Multiple sclerosis (MS) is an immune-mediated chronic inflammatory disease of the central nervous system (CNS) of unknown etiology. The contribution of B lymphocytes to the pathogenesis of MS is well established. The elimination of B cells with monoclonal antibodies suppresses MS activity (Bar-Or et al., 2008; Hauser et al., 2008; Naismith et al., 2010; Kappos et al., 2011b; Sorensen et al., 2014) notably without reducing immunoglobulins in the cerebrospinal fluid (CSF) (Cross and Waubant, 2011) . B cells migrate across the blood-brain barrier in MS patients (von Budingen et al., 2012) . The precise mechanism of B cell traffic through the blood-brain barrier in MS is not known; however, matrix metallopeptidase-9 (MMP-9 (aka gelatinase B)) produced by activated B cells (Trocme et al., 1998) has emerged as one of the key pathogenic molecules which disrupts the blood-brain barrier and degrades myelin basic protein (Chandler et al., 1995; Asahi et al., 2001 ). B cell accumulation in the CSF correlates with acute brain inflammation and intrathecal production of MMP-9 (Kuenz et al., 2008) , while drugs used to treat MS decrease the expression of MMPs (Leppert et al., 2001; Kurzepa et al., 2005) . Additionally, serum MMP-9 levels are increased in MS patients during clinical relapses and in patients with active lesions on brain MRI (Lee et al., 1999) . To date, the expression level of MMP-9 in B cells during MS exacerbation has not been studied.
Regulation of MMP-9 expression in B cells is complicated and includes VLA-4-mediated pathway (Redondo-Munoz et al., 2006) targeted by disease-modifying treatments in MS (Kappos et al., 2011a) . As recent studies suggest that the complex polygenic susceptibility described in MS is likely to be anchored in the regulatory elements outside of protein-coding genes (Maurano et al., 2012) , we decided to explore whether microRNAs (miRNAs) impact MMP-9 expression in B cells of MS patients. MicroRNAs are small, endogenous noncoding RNAs that direct posttranscriptional regulation of protein-coding gene expression by binding to partially complementary sites of target messenger RNAs (mRNAs), resulting in translation repression or mRNA deadenylation and degradation (Ambros, 2004) . Different lineages of cells have unique miRNA expression profiles (Davidson-Moncada et al., 2010) . miRNAs are closely involved in B cell regulation (Sonkoly et al., 2008; Lu and Liston, 2009; Davidson-Moncada et al., 2010; O'Connell et al., 2010) . Expression of select miRNAs has been found to be impaired in B cells of patients with stable MS (Sievers et al., 2012) . However, the impact of miRNAs on B cell function relevant to maintenance of MS activity is not understood.
The present study shows that MS patients during disease exacerbation have up-regulated expression of MMP-9 associated with decreased
